These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 20428688)

  • 81. Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.
    Caldas IS; Menezes APJ; Diniz LF; Nascimento ÁFDSD; Novaes RD; Caldas S; Bahia MT
    Acta Trop; 2019 Jan; 189():30-38. PubMed ID: 30290285
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
    Francisco AF; Lewis MD; Jayawardhana S; Taylor MC; Chatelain E; Kelly JM
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4653-61. PubMed ID: 26014936
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.
    Gaspar L; Coron RP; KongThoo Lin P; Costa DM; Perez-Cabezas B; Tavares J; Roura-Ferrer M; Ramos I; Ronin C; Major LL; Ciesielski F; Pemberton IK; MacDougall J; Ciapetti P; Smith TK; Cordeiro-da-Silva A
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006180. PubMed ID: 29357372
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
    Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection.
    Strauss M; Lo Presti MS; Bazán PC; Baez A; Fauro R; Esteves B; Sanchez Negrete O; Cremonezzi D; Paglini-Oliva PA; Rivarola HW
    Parasitol Int; 2013 Jun; 62(3):293-9. PubMed ID: 23500720
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
    Palace-Berl F; Pasqualoto KFM; Zingales B; Moraes CB; Bury M; Franco CH; da Silva Neto AL; Murayama JS; Nunes SL; Silva MN; Tavares LC
    Eur J Med Chem; 2018 Jan; 144():29-40. PubMed ID: 29247858
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Isoxazolylnaphthoquinone effects on the growth of Trypanosoma cruzi.
    Amuchástegui PI; Moretti ER; Basso B; Sperandeo N; de Bertorello MM
    Rev Argent Microbiol; 1990; 22(4):199-207. PubMed ID: 2129475
    [TBL] [Abstract][Full Text] [Related]  

  • 88. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
    Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
    Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
    Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
    Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box.
    Cantizani J; Gamallo P; Cotillo I; Alvarez-Velilla R; Martin J
    PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009602. PubMed ID: 34270544
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Phenotypic Evaluation of Nucleoside Analogues against
    Fiuza LFA; Batista DGJ; Girão RD; Hulpia F; Finamore-Araújo P; Aldfer MM; Elmahallawy EK; De Koning HP; Moreira O; Van Calenbergh S; Soeiro MNC
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36432189
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Advances in Chagas disease drug development: 2009-2010.
    Buckner FS; Navabi N
    Curr Opin Infect Dis; 2010 Dec; 23(6):609-16. PubMed ID: 20885320
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Identification of inhibitors as drug candidates against Chagas disease.
    Araujo SC; de Angelo RM; Barbosa H; Costa-Silva TA; Tempone AG; Lago JHG; Honorio KM
    Eur J Med Chem; 2023 Feb; 248():115074. PubMed ID: 36623331
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Trypanosoma cruzi targets for new chemotherapeutic approaches.
    Soeiro MN; de Castro SL
    Expert Opin Ther Targets; 2009 Jan; 13(1):105-21. PubMed ID: 19063710
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A decade of targets and patented drugs for chemotherapy of Chagas disease.
    Duschak VG
    Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):216-59. PubMed ID: 21824073
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
    Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
    Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Chagas Disease Chemotherapy: What Do We Know So Far?
    Zuma AA; de Souza W
    Curr Pharm Des; 2021; 27(38):3963-3995. PubMed ID: 33593251
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Novel Therapeutic Options for Chagas Disease Based on Bioactive Compounds from Algae, Bacteria and Fungi Species.
    da Silva MV; Gondim BLC; de Carvalho-Costa TM; Mendes MT; Lemes MR; Barbosa RM; Cardoso TN; Nascimento NS; Barros DB; da Silva MV; Machado JR; Castellano LRC
    Curr Med Chem; 2021; 28(36):7513-7528. PubMed ID: 34365936
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Chagas disease: progress and new perspectives.
    Sánchez-Sancho F; Campillo NE; Páez JA
    Curr Med Chem; 2010; 17(5):423-52. PubMed ID: 20015038
    [TBL] [Abstract][Full Text] [Related]  

  • 100. In Silico Drug Repositioning for Chagas Disease.
    Bellera CL; Alberca LN; Sbaraglini ML; Talevi A
    Curr Med Chem; 2020; 27(5):662-675. PubMed ID: 31622200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.